Table II.
BCL9 expression and clinicopathological features.
| BCL9 expression, n (%) | ||||
|---|---|---|---|---|
| Clinicopathological features | No. of patients | Negative | Positive | P-value |
| Preoperative PSA (ng/ml) | 0.326 | |||
| <10 | 79 | 39 (49.4) | 40 (50.6) | |
| ≥10 | 19 | 7 (36.8) | 12 (63.2) | |
| Gleason score | 0.016 | |||
| ≤6 | 33 | 22 (66.7) | 11 (33.3) | |
| 7 | 54 | 21 (38.9) | 33 (61.1) | |
| ≥8 | 11 | 3 (27.3) | 8 (72.7) | |
| Pathological tumor stage | 0.073 | |||
| pT2 | 68 | 36 (52.9) | 32 (47.1) | |
| pT3-pT4 | 30 | 10 (33.3) | 20 (66.7) | |
| Surgical margin status | 0.111 | |||
| Negative | 81 | 41 (50.6) | 40 (49.4) | |
| Positive | 17 | 5 (29.4) | 12 (70.6) | |
| Biochemical recurrence | 0.020 | |||
| Negative | 80 | 42 (52.5) | 38 (47.5) | |
| Positive | 18 | 4 (22.2) | 14 (77.8) | |
BCL9, B-cell lymphoma 9; PSA, prostate-specific antigen.